Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival

ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. OTLK, a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that members of management will be presenting at and sponsoring the Telluride Retina Film Festival taking place February 3-5, 2022 in Telluride, Colorado.

As part of the event, Outlook Therapeutics will present a corporate overview. To learn more about the event, please visit tellurideretinafilmfestival.org.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:

Harriet Ullman

Vice President

LaVoie Health Science

T: 617-669-3082

hullman@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247 

OTLK@jtcir.com



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!